Join Dementia Research News

The NorAD – Guanfacine study

28 March 2017

Dr Paresh Malhotra, Chief Investigator for this study

This new study aims to assess whether a medication called Guanfacine can improve thinking, particularly attention, in people with Alzheimer’s Disease when given alongside other standard medication. We caught up with Dr Paresh Malhotra, Chief Investigator on this study, to find out more: What are the main aims of the study? Guanfacine itself is licensed for […]

Are attention and brain activity connected to visual memory problems in people with Alzheimer’s?

22 March 2017

Dr Moreno Coco, Chief Investigator of the study

Understanding how an individual’s memory performance changes when affected by Alzheimer’s and the relation between visual attention and memory could contribute to improvements in diagnosing the disease. The ‘Formation, maintenance and use of top-down knowledge in Alzheimer Dementia’ study will therefore explore these factors to gain better insight. We spoke to Dr Moreno Coco, Chief […]

Join Dementia Research user survey results

17 March 2017

Combined cells magenta

In the Autumn 2016 newsletter, Join Dementia Research registrants were invited to complete a survey about their experience of the service*. Some key findings from the survey include:   For those that registered through one of the charity helplines: For those that registered through the website:   For those that matched to studies:   The […]

PROSPECT-M-UK Study

16 March 2017

BRAIN spark

Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Cortico-Basal syndrome (CBS) are all degenerative brain conditions for which there is not currently any curative treatments. They are often initially diagnosed as Parkinson’s disease but are very distinct with an approximate survival of 6-7 years from diagnosis. The PROSPECT-M-UK study aims to develop better methods of […]

‘Tooth loss link to increased risk of dementia’ – NHS Choices

10 March 2017

Miniumum_size_logo

This article has been reproduced from the NHS Choices website. “Dementia breakthrough: Brushing your teeth ‘can help ward off devastating condition’,” reads the Daily Express. The news is based on a study that found tooth loss was associated with an increased risk of dementia. The study involved more than 1,500 elderly people in Japan who […]

Dementia Early Stage Cognitive Aids New Trial (DESCANT)

6 March 2017

Professor David Challis, Chief Investigator for DESCANT

It is known that people developing dementia in its early stages can respond to timely offers of help at home to enhance their experience and coping with dementia, over and above early diagnosis and support now routinely provided in many areas. One such type of help is advice alongside the use of memory aids and […]

What dementia research studies are taking place in Wales?

1 March 2017

Welsh flag

On this St David’s Day 2017, we look at studies on Join Dementia Research that are currently recruiting in Wales. Young-onset Alzheimer’s disease affects people before the age of 65. At the moment very little is known about why some people develop Alzheimer’s disease at such a young age. To try and better understand this, […]

Psychological Stress – Carers of those with Dementia

22 February 2017

Amelia Stone, Chief Investigator on this study

There are currently 550,000 carers in England, who provide essential primary care to individuals living with a diagnosis of dementia. This study will help individuals taking part to identify any current stress they might be under, the factors which may be affecting it, and how it may be improved. We caught up with Amelia Stone, […]

Heading footballs ‘linked to brain damage in professional players’

17 February 2017

Man playing football 251

This article has been reproduced from the NHS Choices website.  “As evidence of dementia link to football emerges is it time to stop kids heading the ball?” is the question on the front page of the Daily Mirror. The headline was prompted by the results of a small study where post-mortems were carried out on […]

A response to the Merck announcement on Verubecestat study

16 February 2017

New AS logo

This news post was originally featured on the Alzheimer’s Society website.  Today, the global healthcare company Merck has announced that it is stopping the EPOCH study, a phase 2/3 study evaluating Verubecestat in people with mild-to-moderate Alzheimer’s disease. Verubecestat is an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) […]

1 2 3 4 28